Get the Stockscreener App
6.01
2.04%
0.12
After Hours:
6.01
Alpha Cognition Inc stock is traded at $6.01, with a volume of 52,397.
It is up +2.04% in the last 24 hours and up +6.00% over the past month.
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
See More
Previous Close:
$5.89
Open:
$6
24h Volume:
52,397
Relative Volume:
0.53
Market Cap:
$96.28M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-2.1237
EPS:
-2.83
Net Cash Flow:
$-7.41M
1W Performance:
-9.08%
1M Performance:
+6.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.75
$6.2625
1-Week Range:
$5.52
$6.65
52-Week Range:
$4.66
$7.00
Alpha Cognition Inc Stock (ACOG) Company Profile
Name
Alpha Cognition Inc
Sector
Industry
Phone
(858) 344-4375
Address
1200-750 W PENDER ST, VANCOUVER
Compare ACOG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
6.01 | 96.28M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alpha Cognition Inc Stock (ACOG) Latest News
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) - Newsfile
Stonegate Capital Partners Initiates Coverage on Alpha Cognition's Innovative Alzheimer's Therapy ZUNVEYL - Citybuzz
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - The Manila Times
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - GlobeNewswire Inc.
Alpha Cognition to delist from Canadian Securities Exchange - MSN
Moves at FDA, NIH - BioCentury
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - BioSpace
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon - Verywell Health
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch - TipRanks
Alpha Cognition Expands Leadership Team Ahead of Landmark Alzheimer's Drug Launch in 2025 - StockTitan
Top Dividend Stocks For Reliable Income In January 2025 - Simply Wall St
Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS - News & Insights
Alpha Cognition Inks $44M Deal With China's CMS to License Alzheimer's Drug in Asia and Beyond - dallasinnovates.com
Alpha Cognition licenses ZUNVEYL in Asia and Oceania By Investing.com - Investing.com Canada
ACOG News Today | Why did Alpha Cognition stock go up today? - MarketBeat
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China - AOL
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - The Manila Times
Alpha Cognition licenses ZUNVEYL in Asia and Oceania - Investing.com India
China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL - TipRanks
Alpha Cognition Lands $44M ZUNVEYL Licensing Deal for Massive Asian Alzheimer's Market - StockTitan
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - BioSpace
Alpha Cognition Sets Launch Strategy Call for Breakthrough Alzheimer's Drug ZUNVEYL - StockTitan
Alpha Cognition files to sell 1.45M common shares for holders - MSN
Alpha Cognition announces private sale of equity securities - Investing.com
Alpha Cognition stock hits 52-week low at $5.3 amid market challenges - Investing.com Australia
Alpha Cognition Raises $52.8 Million in Stock Offering - TipRanks
Alpha Cognition Raises $52.8M in Nasdaq IPO, Strengthens Alzheimer's Drug Commercialization Plans - StockTitan
Alpha Cognition Reports Promising Data for Brain Injury Drug - TipRanks
CSE Bulletin: DelistAlpha Cognition Inc. (ACOG) - Newsfile
Alpha Cognition Announces Voluntary Delisting from CSE - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment - MSN
Alpha Cognition Exits CSE to Focus on Nasdaq Listing, Streamlines Trading Strategy - StockTitan
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment | 2024-12-11 | Investing News - Stockhouse Publishing
Alpha Cognition Announces Positive Interim Pre-Clinical Data for Alpha-1062 Use in A Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Marketscreener.com
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - BioSpace
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Inc. announced that it expects to receive $46.149996 million in funding - Marketscreener.com
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - BioSpace
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com India
Alpha Cognition director Leonard Mertz acquires $49,996 in shares By Investing.com - Investing.com South Africa
Alpha cognition director John Havens buys $24,995 in common shares By Investing.com - Investing.com Nigeria
Alpha Cognition director Leonard Mertz acquires $49,996 in shares - Investing.com
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 By Investing.com - Investing.com UK
Alpha Cognition Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Alpha Cognition Inc (ACOGF) Quarterly 10-Q Report - Quartz
Alpha Cognition prices $50M stock offering - MSN
Canada market stock losers: Tidewater Renewables Ltd. looses 12.43% while Rektron Group Inc dips by 10.33% during mid day trading - Business Upturn
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing - Business Wire
Canada Market Top Losers: AYR Wellness down 47.30%, Trulieve Cannabis falls 40%, - Business Upturn
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):